BTIG Downgrades Boston Scientific (BSX) to Neutral

BTIG downgraded Boston Scientific (NYSE: BSX) from Buy to Neutral on valuation.

Analyst Sean Lavin said, "With shares having run significantly from a low near $5, we believe BSX is priced for 'perfection.' While we expect rev growth and OM expansion to continue, we are not sure future results will mimic the extraordinary Q1 and believe risk now equals reward. We continue to like new products but do note some minor risks and feel Q1 surgical market growth could slow."

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $22.37 yesterday.

You May Also Be Interested In

• Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
• Piper Sandler Upgrades SmartFinancial (SMBK) to Overweight 'on Risk/Reward Dynamic for Clean Bank Under TBVPS'
• Citi Downgrades ICICI Prudential Life Insurance Co Ltd. (IPRU:IN) to Neutral